4WO Stock Overview
Engages in the research, development, manufacturing, and sales of transcatheter valve therapeutic and neurointerventional procedural medical devices in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Peijia Medical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.62 |
| 52 Week High | HK$0.66 |
| 52 Week Low | HK$0.33 |
| Beta | 0.45 |
| 1 Month Change | 5.98% |
| 3 Month Change | 18.10% |
| 1 Year Change | n/a |
| 3 Year Change | -13.89% |
| 5 Year Change | n/a |
| Change since IPO | -79.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4WO | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 8.8% | -5.6% | -0.9% |
| 1Y | n/a | -14.7% | 14.1% |
Return vs Industry: Insufficient data to determine how 4WO performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how 4WO performed against the German Market.
Price Volatility
| 4WO volatility | |
|---|---|
| 4WO Average Weekly Movement | 11.4% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 4WO's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4WO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 1,047 | Yi Zhang | www.peijiamedical.com |
Peijia Medical Limited, together with its subsidiaries, engages in the research, development, manufacturing, and sales of transcatheter valve therapeutic and neurointerventional procedural medical devices in the People’s Republic of China. It operates through Transcatheter Valve Therapeutic Business, Neurointerventional Business, and Future Technology Business segments. The company products include transcatheter aortic valve replacement (TAVR) systems, crosslinked dry-tissue and polymeric tri leaflet TAVR systems, transcatheter aortic valve systems, transseptal mitral valve replacement systems, transfemoral balloon catheter, introducer sheath, pre-shaped guidewire, detachable coils, balloon guide catheter, aspiration catheter, stent retriever, delivery balloon dilatation catheter, balloon dilatation catheter, microcatheter, micro guidewire, micro guidewire, guide catheter, distal access guide catheter, intermediate catheter, and power supply.
Peijia Medical Limited Fundamentals Summary
| 4WO fundamental statistics | |
|---|---|
| Market cap | €426.74m |
| Earnings (TTM) | -€27.77m |
| Revenue (TTM) | €75.44m |
Is 4WO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4WO income statement (TTM) | |
|---|---|
| Revenue | CN¥615.48m |
| Cost of Revenue | CN¥181.86m |
| Gross Profit | CN¥433.62m |
| Other Expenses | CN¥660.20m |
| Earnings | -CN¥226.58m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.35 |
| Gross Margin | 70.45% |
| Net Profit Margin | -36.81% |
| Debt/Equity Ratio | 12.1% |
How did 4WO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 16:48 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Peijia Medical Limited is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Yu | China International Capital Corporation Limited |
| Yuan Gao | China International Capital Corporation Limited |
| Wen Dai | Huatai Research |